<DOC>
	<DOCNO>NCT01686529</DOCNO>
	<brief_summary>The aim study investigate efficacy safety subconjunctival bevacizumab application adjuvant therapy primary pterygium .</brief_summary>
	<brief_title>Bevacizumab Primary Pterygium Treatment</brief_title>
	<detailed_description />
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients primary pterygium Patients diabetes mellitus collagenopathies , previous ocular surgery , pregnant lactating patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pterygium</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>autoconjunctival graft</keyword>
</DOC>